Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines

BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer. In order to establish a possible gene expression response to lapatinib, a panel of breast cancer cell lines wit...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neill, Fiona, Madden, Stephen F, Aherne, Sinead T, Clynes, Martin, Crown, John, Doolan, Padraig, O’Connor, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439312/
https://www.ncbi.nlm.nih.gov/pubmed/22709873
http://dx.doi.org/10.1186/1476-4598-11-41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439312/
https://www.ncbi.nlm.nih.gov/pubmed/22709873
http://dx.doi.org/10.1186/1476-4598-11-41

Ejemplares similares